Status:
COMPLETED
Evaluation of Long Term Immunity Following HPV Vaccination
Lead Sponsor:
Murdoch Childrens Research Institute
Collaborating Sponsors:
Department of Foregin Affairs and Trade, Australia
Ministry of Health, Fiji
Conditions:
Cervical Cancer
Anogenital Warts
Eligibility:
FEMALE
15-17 years
Brief Summary
In Fiji, cervical cancer is the second most frequent cancer and the highest cause of cancer mortality in women. In 2008/9, the Ministry of Health in Fiji accepted a donation of 110,000 doses of quadri...
Detailed Description
In 2008/9, the Ministry of Health (MoH) in Fiji accepted a donation of 110,000 doses of quadrivalent HPV vaccine, Gardasil® based on the high cervical cancer disease burden. There was enough vaccine t...
Eligibility Criteria
Inclusion
- Girls who live in Suva and were previously vaccinated with one, two or three Gardasil® doses or were eligible but did not receive Gardasil® vaccine in the 2008/9 campaign will be eligible for the study.
Exclusion
- Any participant who had anaphylaxis following a previous dose of the vaccine, anaphylaxis to any vaccine component, or possible pregnancy will be excluded from this study.
- In addition, any participant whose dates of previous Gardasil® vaccination are uncertain, or has received Cervarix® vaccine previously, or has an axillary temperature greater than 38°C will be excluded from this study.
Key Trial Info
Start Date :
February 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2015
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT02276521
Start Date
February 1 2015
End Date
March 1 2015
Last Update
September 23 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Colonial War Memorial Hospital
Suva, Fiji